News Releases
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
November 4, 2021- Fully Enrolled Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative Colitis -
-
November 1, 2021- Webcast to be Held at 8:00 am ET on November 4, 2021 -
-
October 28, 2021- Top-Line Data Expected in the Second Quarter of 2022 -
-
October 27, 2021- Represents the First Time Patients Will Be Treated With the Company's Potentially Best-In-Class RORγt Inverse Agonist -
-
October 14, 2021
-
September 28, 2021- Three Abstracts, Including One Late-Breaker, to be Presented on IMU-838, the Company's Selective Oral DHODH Inhibitor, at the 37th Congress of ECTRIMS -
-
September 22, 2021- Preclinical Combination Data Suggests Extra-Ordinary Synergy Between Certain DHODH Inhibitors and Nucleoside Analogues -